Christopher Maisel, MD
Hematology & Oncology · Dallas, TXNPI 1275575185
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $607,191 of the $713,019 with a category attached, or 85.2%. It is spread thinly across 47 manufacturers, the largest accounting for just 20.1%. Reporting peaked in 2022 at $146,093 and has fallen 55.0% since, to $65,767 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 754 payments — averaging $945.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$144K
- Blueprint Medicines Corporation$106K
- Johnson & Johnson$92K
- ADC Therapeutics America, Inc.$79K
- Karyopharm Therapeutics Inc.$76K
- E.r. Squibb & Sons, L.L.C.$40K
- plus $177K from 41 others
Across 131 payments — averaging $8203.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1M
- AbbVie$40K
What the payments were for
- Consulting fees$59,0108%
- Speaking & faculty fees$607,19185%
- Travel & lodging$33,5785%
- Food & beverage$12,9852%
- Education$2560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$713,019 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 74 | $1,081,378 |
| RevlimidLenalidomide | 61 | $845,130 |
| JakafiRuxolitinib Phosphate | 37 | $610,046 |
| PomalystPomalidomide | 24 | $545,583 |
| Lenalidomide | 41 | $494,504 |
| CalquenceAcalabrutinib Maleate | 26 | $396,025 |
| ImbruvicaIbrutinib | 19 | $310,787 |
| NinlaroIxazomib Citrate | 19 | $227,318 |
| Deferasirox | 14 | $70,559 |
| XareltoRivaroxaban | 28 | $35,931 |
| EliquisApixaban | 36 | $34,066 |
| ValacyclovirValacyclovir Hcl | 54 | $2,571 |
| Methadone Hcl | 16 | $1,455 |
| Hydroxyurea | 55 | $1,090 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $67 | $1,081,37874 claims |
| Bristol Myers SquibbRevlimid | $31,037 | $845,13061 claims |
| Incyte CorporationJakafi | $19,497 | $610,04637 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $39,627 | $545,58324 claims |
| AstraZenecaCalquence | $25,100 | $396,02526 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $22,481 | $227,31819 claims |
| Johnson & JohnsonXarelto | $92,434 | $35,93128 claims |
| PfizerEliquis | $128 | $34,06636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
- Devesh PandyaHouston$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.